Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Kiialainen A, Adamkewicz JI, Petry C, Oldenburg J, Pipe SW, Young G, Mahlangu J, Lehle M, Niggli M, Castaman G, Jiménez-Yuste V, Shima M, Négrier C, Schmitt C. Kiialainen A, et al. Res Pract Thromb Haemost. 2023 Dec 29;8(1):102306. doi: 10.1016/j.rpth.2023.102306. eCollection 2024 Jan. Res Pract Thromb Haemost. 2023. PMID: 38282901 Free PMC article.
Inhibitor development and mortality in non-severe hemophilia A.
Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, Fijnvandraat K; INSIGHT Study Group. Eckhardt CL, et al. J Thromb Haemost. 2015 Jul;13(7):1217-25. doi: 10.1111/jth.12990. Epub 2015 Jun 10. J Thromb Haemost. 2015. PMID: 25912309 Free article.
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Matsushita T, et al. N Engl J Med. 2023 Aug 31;389(9):783-794. doi: 10.1056/NEJMoa2216455. N Engl J Med. 2023. PMID: 37646676 Clinical Trial.
Outcomes and outcome measures.
Castaman G, Jimenez-Yuste V, Gouw S, D'Oiron R. Castaman G, et al. Haemophilia. 2024 Apr;30 Suppl 3:112-119. doi: 10.1111/hae.14990. Epub 2024 Mar 19. Haemophilia. 2024. PMID: 38504408
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies.
Mahlangu J, Jiménez-Yuste V, Ventriglia G, Niggli M, Barlera S, Hermans C, Lehle M, Chowdary P, Jew L, Windyga J, Frenzel L, Schmitt C, Castaman G, Pipe SW. Mahlangu J, et al. Res Pract Thromb Haemost. 2024 Mar 1;8(2):102364. doi: 10.1016/j.rpth.2024.102364. eCollection 2024 Feb. Res Pract Thromb Haemost. 2024. PMID: 38559572 Free PMC article.
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, Jiménez Yuste V, Matsushita T, Høgh Nielsen AR, Sathar J, Sutton C, Šaulytė Trakymienė S, Tran H, Villarreal Martinez L, Wheeler AP, Windyga J, Young G, Thaung Zaw JJ, Eichler H. Chowdary P, et al. Among authors: jimenez yuste v. Lancet Haematol. 2024 Dec;11(12):e891-e904. doi: 10.1016/S2352-3026(24)00307-7. Epub 2024 Nov 6. Lancet Haematol. 2024. PMID: 39521008 Free article. Clinical Trial.
284 results